Susquehanna International Group
MRTX

Susquehanna International Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Susquehanna International Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-256,400
Closed -$15.1M – 13834
2023
Q4 		$15.1M Buy
256,400
+215,300
+524% +$12.1M ﹤0.01% 2120
2023
Q3 		$1.79M Sell
41,100
-18,800
-31% -$671K ﹤0.01% 5353
2023
Q2 		$2.16M Buy
59,900
+20,800
+53% +$857K ﹤0.01% 4987
2023
Q1 		$1.45M Sell
39,100
-72,100
-65% -$3.24M ﹤0.01% 5879
2022
Q4 		$5.04M Sell
111,200
-16,000
-13% -$1.04M ﹤0.01% 3214
2022
Q3 		$8.88M Buy
127,200
+67,200
+112% +$4.97M ﹤0.01% 2327
2022
Q2 		$4.03M Buy
60,000
+23,900
+66% +$1.52M ﹤0.01% 3551
2022
Q1 		$2.97M Sell
36,100
-14,400
-29% -$1.47M ﹤0.01% 4642
2021
Q4 		$7.41M Buy
50,500
+7,600
+18% +$1.18M ﹤0.01% 3125
2021
Q3 		$7.59M Buy
42,900
+11,000
+34% +$1.77M ﹤0.01% 3278
2021
Q2 		$5.15M Sell
31,900
-65,900
-67% -$10.6M ﹤0.01% 3987
2021
Q1 		$16.8M Buy
97,800
+25,300
+35% +$5.01M ﹤0.01% 2105
2020
Q4 		$15.9M Sell
72,500
-700
-1% -$151K ﹤0.01% 1979
2020
Q3 		$12.2M Sell
73,200
-3,100
-4% -$424K ﹤0.01% 1968
2020
Q2 		$8.71M Buy
76,300
+400
+0.5% +$38.8K ﹤0.01% 2296
2020
Q1 		$5.83M Sell
75,900
-40,100
-35% -$3.6M ﹤0.01% 2386
2019
Q4 		$14.9M Sell
116,000
-126,100
-52% -$12.2M ﹤0.01% 1687
2019
Q3 		$18.9M Sell
242,100
-6,100
-2% -$572K 0.01% 1374
2019
Q2 		$25.6M Buy
248,200
+209,400
+540% +$16.3M 0.01% 1112
2019
Q1 		$2.84M Buy
38,800
+4,600
+13% +$313K ﹤0.01% 3206
2018
Q4 		$1.45M Sell
34,200
-82,900
-71% -$3.3M ﹤0.01% 4032
2018
Q3 		$5.51M Buy
117,100
+60,400
+107% +$3.36M ﹤0.01% 2572
2018
Q2 		$2.79M Buy
56,700
+38,800
+217% +$1.47M ﹤0.01% 3487
2018
Q1 		$550K Buy
17,900
+7,600
+74% +$211K ﹤0.01% 6435
2017
Q4 		$188K Sell
10,300
-50,600
-83% -$785K ﹤0.01% 8327
2017
Q3 		$713K Buy
+60,900
New +$352K ﹤0.01% 5895
2017
Q2 		– Sell
-15,000
Closed -$78K – 9993
2017
Q1 		$78K Buy
15,000
+3,600
+32% +$19.7K ﹤0.01% 8481
2016
Q4 		$54K Buy
+11,400
New +$62K ﹤0.01% 9274
2016
Q3 		– Sell
-26,200
Closed -$143K – 9208
2016
Q2 		$143K Buy
+26,200
New +$418K ﹤0.01% 7850
2016
Q1 		– Sell
-37,400
Closed -$1.18M – 9834
2015
Q4 		$1.18M Sell
37,400
-18,200
-33% -$643K ﹤0.01% 5091
2015
Q3 		$1.91M Buy
55,600
+38,500
+225% +$1.16M ﹤0.01% 4366
2015
Q2 		$538K Buy
+17,100
New +$504K ﹤0.01% 7493

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's MRTX Position: Q1 2024 in Review

Susquehanna International Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 145,890 shares — an estimated $8.57M sold.

Susquehanna International Group first reported a position in MRTX in Q2 2015 and held it in 29 quarters. The position peaked at $15.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Susquehanna International Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 145,890 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $8.57M.
  • Susquehanna International Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 29 quarters.
  • Susquehanna International Group's Mirati Therapeutics, Inc. Common Stock position peaked at $15.7M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.